Inactive Instrument

Highlights Adamas Pharmaceuticals, Inc.

Equities

ADMS

US00548A1060

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Supernus Pharmaceuticals, Inc. completed the acquisition of Adamas Pharmaceuticals, Inc. from Mohr Davidow Ventures and others.	21-11-23	CI
Adamas Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-10	CI
NASDAQ 100 : Top Midday Gainers	21-10-11	MT
Supernus Pharmaceuticals : to Buy Adamas for $400 Million Upfront Plus Further Boost Based on Parkinson's Disease Drug Sales	21-10-11	MT
Supernus Pharmaceuticals : to Buy Adamas Pharmaceuticals for up to $9.10 per Share in Cash, Contingent Value Rights Deal	21-10-11	MT
Supernus Pharmaceuticals : bolsters Parkinson's portfolio with $400 mln deal for Adamas Pharma	21-10-11	RE
Supernus Pharmaceuticals : to buy Adamas Pharma for about $400 mln	21-10-11	RE
Supernus Pharmaceuticals, Inc. made an offer to to acquire Adamas Pharmaceuticals, Inc. from Mohr Davidow Ventures and others for approximately $390 million.	21-10-10	CI
Adamas Pharmaceuticals : Earnings Flash (ADMS) ADAMAS PHARMACEUTICALS Reports Q2 Revenue $22M, vs. Street Est of $21.8M	21-08-09	MT
Adamas Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-09	CI
Adamas Pharmaceuticals : Wins Patents for Parkinson's, Epilepsy Drugs	21-07-22	MT
Adamas Pharmaceuticals, Inc. Announces the Publication of A New Data Analysis Titled	21-06-10	CI
Adamas Pharmaceuticals : Earnings Flash (ADMS) ADAMAS PHARMACEUTICALS Posts Q1 Revenue $19.3M, vs. Street Est of $19.7M	21-05-10	MT
Adamas Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-10	CI
Adamas Pharmaceuticals, Inc. Publishes New Data Analyses Demonstrating Gocovri Treatment More Than Doubled on Time without Dyskinesia in Patients with Parkinson’s Disease	21-03-29	CI
Adamas Pharmaceuticals : Pharma Narrows Q4 Loss As revenue Rises, Sets Guidance -- Stock Down 2% After-Hours	21-02-23	MT
Adamas Pharmaceuticals : Earnings Flash (ADMS) ADAMAS PHARMACEUTICALS Posts Q4 EPS $-0.64, vs. Street Est of $-0.52	21-02-23	MT
Adamas Pharmaceuticals : Earnings Flash (ADMS) ADAMAS PHARMACEUTICALS Posts Q4 Revenue $21M, vs. Street Est of $20.6M	21-02-23	MT
Adamas Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-02-23	CI
Adamas Pharmaceuticals, Inc. Announces FDA Approval for Second Indication for GOCOVRI® as an Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes	21-02-01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Adamas Pharmaceuticals, Inc.

Equities

ADMS

US00548A1060

Highlights

Filters